HRS: Biosence Webster showcases new ablation technology
Denver—Medical device company Biosense Webster featured its Carto3 3D mapping platform, an upgrade to its CartoXP EP navigation system for viewing and monitoring the heart’s electrical activity, at the 31st annual Heart Rhythm Society (HRS) scientific sessions May 12-15.
The Carto3 system comes equipped with two key features that enable both fast anatomical mapping (FAM) and the ability to visualize the Biosense fixed Lasso NAV circular variable mapping catheter, that uses electromagnetic technology with its miniaturized sensors, Nina Asgari, product director at the company told Cardiovascular Business News.
The new technology will enable physicians performing atrial fibrillation (AF) procedures such as ablation to view the Lasso catheter on the Carto platform.
“This gives electrophysiologists the ability to reconstruct the chamber of the heart by acquiring volume,” said Asgari.
“Because we have a lot of demand for the Carto3, what we have done is used this as a bridging solution for those who do not have the capital budget to upgrade their XP system. This allows them to have the Lasso catheter connected to their existing system for enhanced visualization,” she said.
Asgari said that the Carto3 platform was completely redesigned and gained FDA approval in October/November of this year to allow physicians to visualize any diagnostic catheter and provides the FAM feature to quickly 3D map and reconstruct the heart chambers.
Asgari said, “Any of our future technology will be compatible with the Carto technology because it is robust enough to carry us into the future.”
Additionally, the Diamond Bar, Calif.-based Biosense, a Johnson & Johnson company, featured its Thermocool SF catheter, which recently gained a CE mark of approval for its use throughout Europe.
The Thermocool technology is an irrigated catheter used during ablation procedures to treat cardiac arrhythmias. The technology allows for cooling of the catheter's tip during ablation. The feature allows for better fluid delivery to take place and allows heat to dissolve across the catheters tip.
The Carto3 system comes equipped with two key features that enable both fast anatomical mapping (FAM) and the ability to visualize the Biosense fixed Lasso NAV circular variable mapping catheter, that uses electromagnetic technology with its miniaturized sensors, Nina Asgari, product director at the company told Cardiovascular Business News.
The new technology will enable physicians performing atrial fibrillation (AF) procedures such as ablation to view the Lasso catheter on the Carto platform.
“This gives electrophysiologists the ability to reconstruct the chamber of the heart by acquiring volume,” said Asgari.
“Because we have a lot of demand for the Carto3, what we have done is used this as a bridging solution for those who do not have the capital budget to upgrade their XP system. This allows them to have the Lasso catheter connected to their existing system for enhanced visualization,” she said.
Asgari said that the Carto3 platform was completely redesigned and gained FDA approval in October/November of this year to allow physicians to visualize any diagnostic catheter and provides the FAM feature to quickly 3D map and reconstruct the heart chambers.
Asgari said, “Any of our future technology will be compatible with the Carto technology because it is robust enough to carry us into the future.”
Additionally, the Diamond Bar, Calif.-based Biosense, a Johnson & Johnson company, featured its Thermocool SF catheter, which recently gained a CE mark of approval for its use throughout Europe.
The Thermocool technology is an irrigated catheter used during ablation procedures to treat cardiac arrhythmias. The technology allows for cooling of the catheter's tip during ablation. The feature allows for better fluid delivery to take place and allows heat to dissolve across the catheters tip.